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Abstract
Background: Studies have shown that HIV‑HBV co‑infected patients have an increased risk of liver‑related morbidity 
and mortality compared to their HIV‑mono‑infected counterparts. Furthermore, it has been reported that HIV‑HBV 
co‑infected patients have a significantly high incidence of drug‑induced hepatotoxicity following commencement of 
HAART than HIV‑mono‑infected patients.
Objectives: To compare the levels of aspartate amino transferase (AST), alanine amino transferase (ALT) and alkaline 
phosphatase (ALKPO4) enzyme levels between HAART naïve HIV‑HBV co‑infected patients and their HIV‑mono‑infected 
counterparts.
Materials and Methods: A cross‑sectional descriptive study in which 142 newly diagnosed HIV/HBV co‑infected and 
HIV mono‑infected adults were investigated for alkaline aminotransferase, aspartate aminotransferase and alkaline 
phosphatase enzyme levels.
Results: The study subjects comprised of 80 (56.3%) females and 62 (46.7%) males. The age range of the study 
population was 15‑65 years. The mean ages of male and female subjects were 45.5 ± 10.5 years and 39.1 ± 7.5 years 
respectively (P  < 0.05). Sixty‑three (44.4%) study subjects were HIV/HBV co‑infected while 79 (55.6%) were HIV 
mono‑infected. The mean ALT enzyme level of HIV/HBV co‑infected subjects was significantly higher than that of HIV 
mono‑infected ones i.e., 42.12 IU/l vs. 27.86 IU/l, (P = 0.038). However, there was no statistically significant difference 
in the mean AST (30.14 IU/l vs. 29.09 IU/l, P = 0.893) and ALKPO4 (55.86 IU/l vs. 60.97 IU/l, P = 0.205) enzyme levels 
between HIV‑HBV co‑infected and HIV mono‑infected subjects albeit the two enzymes were moderately elevated in 
both categories of subjects.
Conclusion: The significantly elevated ALT enzyme levels amongst HIV‑HBV co‑infected subjects suggest that HIV‑HBV 
co‑infected patients may have an increased risk of liver‑related morbidity and mortality than their HIV mono‑infected 
counterparts. Screening for serological markers of chronic HBV infection, as well as hepatic transaminase enzyme 
levels in all newly diagnosed HIV‑positive patients is therefore recommended before commencement of HAART.
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Introduction
Areas of the world with the highest hepatitis B virus (HBV) 
endemicity including Nigeria correspond to areas with 
the highest incidence of human immunodeficiency 
virus (HIV) infection.[1‑5] Human immunodeficiency virus 
and HBV co‑infection have been a growing global health 
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problem, especially in underprivileged and underdeveloped 
sub‑Saharan African countries. Nigeria is highly endemic for 
HBV with a chronic HBV prevalence rate of 11‑21% in blood 
donors and 11‑15% in HIV‑infected persons.[2‑5] Although, 
the advent of highly active antiretroviral therapy (HAART) 
has reduced mortality in the HIV‑infected population, it has 
consequently led to an increase in the prevalence of chronic 
co‑infections such as with HBV.[7] According to recent 
research, the rate of HBV co‑infection in HIV‑positive 
patients is increasing.[2,6,7]
Hepatitis B virus has little impact on HIV disease 
progression; however, HIV renders HBV more aggressive 
in co‑infected individuals.[6] Studies have shown that 
HIV‑HBV co‑infected patients are 19 times more likely to 
die of liver‑related mortality than their HIV‑monoinfected 
counterparts.[7,8] Human immunodeficiency virus and HBV 
co‑infection increases hepatotoxicity from highly active 
antiretroviral therapy (HAART) by three to four folds, 
and the risk may be even greater in those with a higher 
CD4+  cell count change indicating a role for immune 
reconstitution. Some studies have also demonstrated 
decreased response to HAART in the setting of chronic 
HBV coinfection.[7,8] This problem is further compounded 
in developing countries like ours by lack of proper funding 
of research programs on HIV‑HBV co‑infection, inadequate 
diagnostic facilities for detecting concurrent diseases in 
HIV‑infected patients (e.g., HBV), lack of facilities for 
detecting early HAART‑related hepatotoxicity, and lack 
of effective HBV treatment; all of which could have a 
great impact on the effective management of this affected 
population. In Nigeria, only a few centers carry out routine 
screening for HBsAg in HIV‑positive patients, as it is not 
yet adopted as a national policy by the government. This 
lapse may continue to expose a lot of HIV‑HBV co‑infected 
patients to HAART‑related hepatotoxicity and other HBV 
associated hepatic disorders.[2,8,9]
With the increasing number of patients accessing HAART 
in Nigeria, HBV coinfection will continue to be a growing 
health concern among HIV‑positive population in the few 
decades to come unless and until our government implements 
a national guideline for the control, as well as management 
of this potential health threat among HIV‑infected persons.
Aim of the study
To compare hepatic transaminase and alkaline phosphatase 
enzymes levels between HAART naïve HIV/HBV 
co‑infected and HIV mono‑infected patients.
Materials and Methods
Study area
The study was carried out at the University of Maiduguri 
Teaching Hospital, North Eastern Nigeria.
Study design
The study was a cross‑sectional descriptive study.
Study population
The study subjects were newly diagnosed HIV‑positive 
adults ≥14 years of age. The study subject were selected 
by systematic random sampling method i.e., every third 
HIV‑positive patient referred to the ART clinic who fulfilled 
the entry criteria was recruited in to the study.
Inclusion criteria





• Patients younger than 14 years of age
• Patients with other causes of chronic liver disease other 
than HBV
• Patients who had tested positive for anti‑HCV antibody
• HIV‑negative patients
• HAART experienced HIV‑positive patients
• HIV‑TB co‑infected patients.
Sample size
Based on HIV prevalence of 3.2% in Borno state, Epi Info 
statistical software was used to calculate the sample size, an 
α‑level of 5% and 1‑β of 80% were used.
Materials and test Methods
On entry into the study, a detailed history was obtained 
and full clinical examination was carried out followed 
by administration of a structured questionnaire to 
each patient, giving detailed demographic, clinical and 
laboratory data.
Five milliliters of blood sample was collected from 
each subject by venepuncture after cleansing site with 
methylated spirit. This was placed in plain tubes and 
allowed to clot. The sera were separated from the 
cells, frozen at −20°C to be tested within 72 h. Blood 
levels of alanine amino transaminase, aspartate amino 
transaminase and alkaline phosphatase enzyme levels 
were subsequently determined using an auto‑analyser. Five 
milliliters of blood sample was collected from each subject 
by venepuncture after cleansing site with methylated 
spirit. This was placed in plain tubes and allowed to clot. 
The serum was separated from the cells, frozen at −20°C 
to be tested within 72 h. Blood levels of alanine amino 
transaminase, aspartate amino transaminase and alkaline 
phosphatase enzyme levels were subsequently determined 
using automatic analyzer (automatic serum analyser, 
RMD Mediaids, PVT Ltd, 301‑302, Magnum House, 
New Delhi‑11015, India).
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Human immunodeficiency virus (HIV) screening test 
was done by the UNIGOLD and DETERMINE rapid test 
methods (UNIGOLD™ Recombigen®/DETERMINE™ 
rapid test, Trinity Biotech, Jamestown NY, USA); positive 
cases were subsequently confirmed by the western blotting 
method method (QualiCode™, Immunetics, Inc, 27 Drydock 
Avenue, 6th floor, Boston, MA, 02210‑2377, USA). Hepatitis 
B surface antigen (HBsAg) test was done using the ELISA 
test method (ELISA, CALTECH, C.A, USA).
Ethical consideration
Ethical approval for the study was obtained from the 
Ethical Committee of the University of Maiduguri Teaching 
Hospital. A signed or thumb‑printed informed consent was 
obtained from the patients before commencing the study. 
Patients were at liberty to deny consent for or opt out of the 
study at any stage without any consequences.
Results
One hundred and forty‑two newly diagnosed HIV positive 
subjects were recruited into the study. Out of these 
80 (56.3%) were females and 62 (43.7%) males. Their ages 
ranged between 15 and 65 years. The mean ages for male and 
female subjects were 45.5 ± 10.5 years and 39.1 ± 7.5 years, 
respectively, (P < 0.05). Sixty‑three (44.4%) subjects were 
HBsAg positive and the remaining 79 (55.6%) were HBsAg 
negative [Table 1].
The distribution of alanine amino transferase (ALT) 
enzyme levels between HBsAg positive and HBsAg 
negative subjects is shown in Table 2. The mean ALT 
level of HBsAg positive patients was 42.12 IU/l and that 
of HBsAg negative patients was 27.86 IU/l, (P = 0.036). 
Moreover, scores of the study subjects (i.e. 31.65%) who 
had serum ALT enzyme levels within normal limits were 
found amongst HBsAg negative individuals, (P = 0.013). 
Conversely, HBsAg positive subjects constituted quite a 
substantial proportion (28.57%) of individuals with ALT 
enzyme levels greater than 5 times the upper limit of 
normal (i.e. >60 IU/l), (P = 0.030).
Table 3 compared the distribution of aspartate amino 
transferase (AST) enzyme levels between HBsAg positive 
and HBsAg negative subjects. The mean AST level 
of HBsAg positive subjects was 30.14 IU/l and that of 
negative ones was 29.09 IU/l. There was no statistically 
significant difference between the two means (P = 0.893). 
However, HBsAg positive subjects constituted a 
statistically significant proportion (i.e. 33.33%) amongst 
individuals with moderately elevated levels of AST 
enzyme (i.e. 25‑36 IU/l), (P = 0.025).
Table 4 compared alkaline phosphatase (AlkPO4) enzyme 
levels between HBsAg positive and negative subjects of 
the study population. The mean AlkPO4 enzyme level of 
HBsAg positive subjects was 55.86 IU/l while that of their 
HBsAg negative counterparts was 60.97 IU/l. There was no 
statistically significant difference between the means of the 
two groups (P = 0.205).
Furthermore, HIV/HBV co‑infected patients have a 
significantly lower mean CD4+ cell counts and higher mean 
ALT enzyme levels compared to their HIV‑monoinfected 
counterparts [Table 5].
Table 1: Age and sex distribution of the study population
Age group (years) Sex
Female N (%) Male N (%) P value
15-19 0 (0.00) 1 (1.70) 0.402
20-24 1 (1.25) 9 (13.56) 0.014*
25-29 13 (17.07) 16 (25.42) 0.321
30-34 13 (17.07) 17 (27.12) 0.240
35-39 21 (26.83) 11 (18.64) 0.331
40-44 8 (9.76) 3 (5.08) 0.368
45-49 8 (9.76) 4 (6.78) 0.589
50-54 2 (2.44) 0 (0.00) 0.228
55-59 12 (14.63) 1 (1.70) 0.013*
≥60 2 (2.44) 0 (0.00) 0.228
*Statistically significant
Table 2: Distribution of alanine amino transferase 
enzyme levels and HBsAg status of the study 
population
ALT levels (IU/L) HBsAg status P value
Positive N (%) Negative N (%)
0-12 3 (4.76) 25 (31.65) 0.013*
13-24 21 (33.33) 28 (35.44) 0.857
25-36 12 (19.05) 8 (10.13) 0.263
37-48 9 (14.29) 6 (7.59) 0.341
49-60 0 (0.00) 4 (5.06) 0.293
>60 18 (28.57) 8 (10.13) 0.030*
Total N (%) 63 (100) 79 (100)
*Statistically significant; HBsAg=Hepatitis B surface antigen; ALT=Alanine 
amino transferase
Table 3: Distribution of aspartate amino transferase 
enzyme levels and HBsAg status of the study 
population
AST levels (IU/L) HBsAg status P value
Positive N (%) Negative N (%)
0-12 18 (28.57) 26 (32.91) 0.705
13-24 18 (28.57) 25 (31.65) 0.787
25-36 21 (33.33) 10 (12.66) 0.025*
37-48 0 (0.00) 4 (5.06) 0.293
49-60 0 (0.00) 4 (5.06) 0.293
>60 6 (9.53) 10 (12.66) 0.694
Total N (%) 63 (100) 79 (100)
*Statistically significant; HBsAg=Hepatitis B surface antigen; 
AST=Aspartate amino transferase
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Discussion
The scourge of the HIV/AIDS pandemic is most felt in 
sub‑Saharan Africa where it has been estimated that 
about 9% of its adult population are living with the 
virus.[10] Nigeria, being the most populous country on 
the African continent will continue to remain vulnerable 
to the threats of HIV/AIDS and other chronic viral 
infections including HBV.[11] There is evidence that 
co‑infection with HBV will contribute significantly 
to morbidity and mortality within the HIV positive 
population over the coming years; this may be partly 
due to increase in survival of HIV‑infected patients as 
a result of accessibility to highly active antiretroviral 
therapy (HAART) in developing countries.[2] Studies 
have shown that HBV co‑infection in the setting of 
HIV complicates the clinical course and management of 
HIV infection.[2] It may also adversely affect therapy for 
HIV infection. The reported co‑infection rates of HIV 
and HBV have been variable worldwide depending on the 
geographic region, risk groups and the type of exposure 
involved.[3] Within Nigeria, various prevalence rates of 
HIV and HBV co‑infections have been reported from 
region to region.
The mean serum alanine amino transferase (ALT) enzyme 
level of HIV‑HBV co‑infected subjects was significantly 
higher than those of HIV mono infected subjects in this 
study. It was also observed in the study that HIV‑HBV 
co‑infected subjects constituted quite a sizable proportion 
of persons with ALT enzyme levels greater than 5 times 
the upper limit of normal (ALT normal range for study 
area/center: 1‑22 IU/l). This may lend credence to the fact 
that HIV‑HBV co‑infected patients have an increased risk 
of liver related morbidity and mortality than their HIV 
mono infected counterparts.[3] Although a comparison of 
the mean aspartate amino transferase (AST) enzyme level 
between HIV‑HBV co‑infected and HIV mono‑infected 
subjects in the study did not reveal any statistically 
significant disparity between the two groups, however 
HIV‑HBV co‑infected subjects constituted a statistically 
significant majority amongst individuals with moderate 
elevation of AST enzyme levels (AST normal limit 
for study area/center: 1‑15 IU/l). These findings were 
similar to those reported by Otedo et al.,[12] in Kenya; 
mean ALT 375 (±213) IU/l for HIV‑HBV co‑infected 
subjects vs. 338 (±135) IU/l for HIV mono‑infected 
subjects (P = 0.05) and mean AST 286 (±117) IU/l for 
HIV‑HBV co‑infected subjects compared with 306 (±175) 
IU/l for HIV mono‑infected subjects (P = 0.230). On the 
contrary, other workers like Rai et al.,[13] in India have 
demonstrated a significant rise in the mean levels of both 
transaminase enzymes in co‑infected subjects compared 
with HIV mono‑infected ones. Conversely, Shazia and 
colleagues[14] working in Mumbai, India, did not find a 
significant rise in the transminase enzyme levels amongst 
both HIV‑HBV co‑infected and HIV mono‑infected 
subjects. Since serum ALT enzyme is more specific to 
the liver, its increase either in isolation or together with 
AST may suggest an active HBV disease. The variation 
in the transaminase enzyme levels in the various studies 
could also reflect the difference in socio‑demographic, 
as well as clinical characteristics of the study populations 
involved.[3]
In a similar vein, it has been observed that there was 
no statistically significant difference between the mean 
serum levels of alkaline phosphatase (AlkPO4) enzyme 
of HIV‑HBV co‑infected subjects and those of HIV 
mono‑infected ones, although the levels were raised in 
both categories of patients (AlkPO4 normal limit for study 
area/center: 60‑170 IU/l). This enzyme is also non‑specific 
to the liver as its level can increase in other disease states 
e.g., HIV infection, bone diseases, chronic renal disease etc. 
This finding is also in concordance with those reported by 
other workers, for example Otedo et al.,[12] in Kenya observed 
that HIV/AIDS patients were more prone to various 
multi‑systemic inflammatory conditions due to dysfunction 
in both qualitative and quantitative cellular immunity 
thereby resulting in the elevation of hepatic transaminases, 
as well as alkaline phosphatase enzyme levels.
Conclusion
The finding of a statistically significant mean serum ALT 
enzyme level among HIV‑HBV co‑infected subjects, as 
well as moderate elevation of AST enzyme level between 
these two sub‑populations (i.e. HIV‑HBV co‑infected and 
HIV mono‑infected subjects) further corroborate the fact 
that HIV‑HBV co‑infected persons may be more prone to 
Table 4: Distribution of alkaline phosphatase (ALKPO
4
) 
enzyme levels and HBsAg status of the study population
ALKPO
4
 (IU/L) HBsAg status P value
Positive N (%) Negative N (%)
0-35 27 (42.86) 23 (29.11) 0.230
36-70 21 (33.33) 24 (30.38) 0.795
71-105 9 (14.29) 22 (27.85) 0.202
>105 6 (9.52) 10 (12.66) 0.694
Total N (%) 63 (100) 79 (100)
HBsAg=Hepatitis B surface antigen
Table 5: Relationship of the mean CD4 cells count and 
the mean enzyme levels between HIV/HBV co‑infected 
and HIV‑monoinfected patients
HIV‑HBV HIV P value
Mean CD4+ cell count (cells/µl) 105.43 161.35 0.038*
Mean ALT (IU/l) 42.12 27.86 0.049*
Mean AST (IU/l) 30.14 29.09 0.893
Mean ALPO
4
 (IU/l) 55.86 60.97 0.205
*Statistically significant; ALPO4=Alkaline phosphatase; HIV=Human 
immunodeficiency virus; HBV=Hepatitis B virus
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liver related complications than their HIV mono infected 
counterparts, and this calls for an intervention. From the 
foregoing, it is pertinent therefore to consider screening all 
HIV infected persons for markers of chronic HBV infection, 
as clinical assessment alone may be unhelpful in identifying 
potentially co‑infected persons.
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